Coagulation

Australian registry will grow evidence for anticoagulation in the obese

A lack of validated on-therapy ranges for the novel oral anticoagulants (NOACs) contributes to the difficulty in managing obese patients with conditions such as pulmonary embolism (PE) or deep vein thrombosis (DVT), a haematology meeting has heard. In addition, there is...

A lack of validated on-therapy ranges for the novel oral anticoagulants (NOACs) contributes to the difficulty in managing obese patients...
Transfusion medicine

Age increases transfusion Hb threshold

Most recipients of blood transfusions are over 65 years of age yet patient blood management guidelines do not consider whether older patients should be treated differently to younger patients. Speaking at the Blood 2018 symposium on Haematology at Extremes of Age,...

Most recipients of blood transfusions are over 65 years of age yet patient blood management guidelines do not consider whether...
Blood cancers

CAR-T cell therapy still on the drawing board over composition & timing

Maximising the curative potential of chimeric antigen receptor (CAR) T cells will require a multi-pronged approach - improving CAR and cell product design, multivalent targeting and optimal timing of use. Speaking to the limbic at Blood 2018, Professor Stan Riddell said...

Maximising the curative potential of chimeric antigen receptor (CAR) T cells will require a multi-pronged approach - improving CAR and...